Vigabatrin (SabrilR)
The Vigabatrin was licensed worldwide, except in the United States because of its toxicity. It’s structural is analog of GABA, binding irreversibly to the active site of GABA-T. Newly synthesized enzymes take 4-6 days to normalize the enzymatic activity. In vivo studies in human and animal subjects have shown that VGB significantly increases extracellular GABA concentrations in the brain. VGB has no other known action.
Advantages
Known mode of action,
Favourable pharmacokinetics,
Easy to use, Few interactions,
No enzyme induction